Literature DB >> 25421518

Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials.

Katie Witkiewitz1, Daniel E Falk, Henry R Kranzler, Raye Z Litten, Kevin A Hallgren, Stephanie S O'Malley, Raymond F Anton.   

Abstract

BACKGROUND: Attrition is common in alcohol clinical trials and the resultant loss of data represents an important methodological problem. In the absence of a simulation study, the drinking outcomes among those who are lost to follow-up are not known. Individuals who drop out of treatment and continue to provide drinking data, however, may be a reasonable proxy group for making inferences about the drinking outcomes of those lost to follow-up.
METHODS: We used data from the COMBINE study, a multisite, randomized clinical trial, to examine drinking during the 4 months of treatment among individuals who dropped out of treatment but continued to provide drinking data (i.e., "treatment dropouts;" n = 185). First, we estimated the observed treatment effect size for naltrexone versus placebo in a sample that included both treatment completers (n = 961) and treatment dropouts (n = 185; total N = 1,146), as well as the observed treatment effect size among just those who dropped out of treatment (n = 185). In both the total sample (N = 1,146) and the dropout sample (n = 185), we then deleted the drinking data after treatment dropout from those 185 individuals to simulate missing data. Using the deleted data sets, we then estimated the effect of naltrexone on the continuous outcome percent heavy drinking days using 6 methods to handle missing data (last observation carried forward, baseline observation carried forward, placebo mean imputation, missing = heavy drinking days, multiple imputation (MI), and full information maximum likelihood [FIML]).
RESULTS: MI and FIML produced effect size estimates that were most similar to the true effects observed in the full data set in all analyses, while missing = heavy drinking days performed the worst.
CONCLUSIONS: Although missing drinking data should be avoided whenever possible, MI and FIML yield the best estimates of the treatment effect for a continuous outcome measure of heavy drinking when there is dropout in an alcohol clinical trial.
Copyright © 2014 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol Use Disorder; Clinical Trials; Continuous Outcome Measure; Missing data; Relapse; Treatment

Mesh:

Year:  2014        PMID: 25421518      PMCID: PMC4244651          DOI: 10.1111/acer.12543

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  23 in total

1.  ML versus MI for Missing Data with Violation of Distribution Conditions.

Authors:  Ke-Hai Yuan; Fan Yang-Wallentin; Peter M Bentler
Journal:  Sociol Methods Res       Date:  2012-11

Review 2.  Measurement of drinking behavior using the Form 90 family of instruments.

Authors:  W R Miller; F K Del Boca
Journal:  J Stud Alcohol Suppl       Date:  1994-12

3.  Alcohol dependence: analysis of factors associated with retention of patients in outpatient treatment.

Authors:  Márcia Fonsi Elbreder; Rebeca de Souza e Silva; Sandra Cristina Pillon; Ronaldo Laranjeira
Journal:  Alcohol Alcohol       Date:  2010-11-30       Impact factor: 2.826

4.  The impact of borderline personality disorder on residential substance abuse treatment dropout among men.

Authors:  Matthew T Tull; Kim L Gratz
Journal:  Drug Alcohol Depend       Date:  2011-09-09       Impact factor: 4.492

5.  Pretreatment and during treatment risk factors for dropout among patients with substance use disorders.

Authors:  John McKellar; John Kelly; Alex Harris; Rudolf Moos
Journal:  Addict Behav       Date:  2005-06-23       Impact factor: 3.913

6.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

7.  A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.

Authors:  Joanne B Fertig; Megan L Ryan; Daniel E Falk; Raye Z Litten; Margaret E Mattson; Janet Ransom; William J Rickman; Charles Scott; Domenic Ciraulo; Alan I Green; Nassima A Tiouririne; Bankole Johnson; Helen Pettinati; Eric C Strain; Eric Devine; Mary F Brunette; Kyle Kampman; David A Tompkins; Robert Stout
Journal:  Alcohol Clin Exp Res       Date:  2012-02-10       Impact factor: 3.455

8.  Substance user treatment dropout from client and clinician perspectives: a pilot study.

Authors:  Rebekka S Palmer; Mary K Murphy; Alessandro Piselli; Samuel A Ball
Journal:  Subst Use Misuse       Date:  2009       Impact factor: 2.164

9.  The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials.

Authors:  Sarra L Hedden; Robert F Woolson; Rickey E Carter; Yuko Palesch; Himanshu P Upadhyaya; Robert J Malcolm
Journal:  J Subst Abuse Treat       Date:  2008-11-13

10.  Stereotyping and the treatment of missing data for drug and alcohol clinical trials.

Authors:  Stephan Arndt
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-02-18
View more
  29 in total

1.  Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.

Authors:  Katie Witkiewitz; Henry R Kranzler; Kevin A Hallgren; Stephanie S O'Malley; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Karl F Mann; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2018-11-05       Impact factor: 3.455

2.  Baseline patterns of substance use disorder severity and depression and anxiety symptoms moderate the efficacy of mindfulness-based relapse prevention.

Authors:  Corey R Roos; Sarah Bowen; Katie Witkiewitz
Journal:  J Consult Clin Psychol       Date:  2017-11

3.  Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.

Authors:  Corey R Roos; Karl Mann; Katie Witkiewitz
Journal:  Addict Biol       Date:  2016-08-02       Impact factor: 4.280

4.  Working memory capacity and addiction treatment outcomes in adolescents.

Authors:  Jon M Houck; Sarah W Feldstein Ewing
Journal:  Am J Drug Alcohol Abuse       Date:  2017-07-20       Impact factor: 3.829

5.  Evaluating a longitudinal mediation model of perceived stress, depressive symptoms, and substance use treatment outcomes.

Authors:  Corey R Roos; Brian D Kiluk; R Kathryn McHugh; Kathleen M Carroll
Journal:  Psychol Addict Behav       Date:  2020-04-16

6.  Broad Coping Repertoire Mediates the Effect of the Combined Behavioral Intervention on Alcohol Outcomes in the COMBINE Study: An Application of Latent Class Mediation.

Authors:  Katie Witkiewitz; Corey R Roos; Davood Tofighi; M Lee Van Horn
Journal:  J Stud Alcohol Drugs       Date:  2018-03       Impact factor: 2.582

7.  Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence.

Authors:  Kelly E Dunn; Joseph A Harrison; Jeannie-Marie Leoutsakos; Dingfen Han; Eric C Strain
Journal:  Alcohol Alcohol       Date:  2016-08-27       Impact factor: 2.826

Review 8.  Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.

Authors:  Brian D Kiluk; Kathleen M Carroll; Amy Duhig; Daniel E Falk; Kyle Kampman; Shengan Lai; Raye Z Litten; David J McCann; Ivan D Montoya; Kenzie L Preston; Phil Skolnick; Constance Weisner; George Woody; Redonna Chandler; Michael J Detke; Kelly Dunn; Robert H Dworkin; Joanne Fertig; Jennifer Gewandter; F Gerard Moeller; Tatiana Ramey; Megan Ryan; Kenneth Silverman; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2015-11-21       Impact factor: 4.492

Review 9.  Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-11       Impact factor: 3.455

Review 10.  Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-06       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.